Celebrating Success: Major Achievement in COMBACTE-CARE

Read more
combacte-care News Item

245 Patients in EURECA

As of today COMBACTE-CARE’s EURECA study has recruited a total of 245 patients. Currently twenty nine sites in nine different countries have been initiated Albania , Croatia, Greece, Kosovo, Montenegro, seven from Spain, Romania and five from Serbia, Turkey).

This month’s top enrolling sites are Clinical Center of Serbia (Dr. Biljana Carevic), Serbia, with 65 patients; Hospital Universitario Reina Sofia (Dr. De la Torre Cisneros), Spain, with 42 patients; the Institute of Public Health of Vojvodina (Dr. Gorana Dragovac), Serbia, with 31 patients and Hospital Universitari de Bellvitge (Dr. Evelyn Shaw), Spain, with 27 patients.

The data is being properly monitored to ensure the quality and accuracy.

EURECA is a very ambitious and challenging study involving 50 sites from 10 countries, aiming at including 2000 patients! All training sessions for participating sites have been done and completed by webcast; a recorded session will be also available for all participants in case they need a refresh some aspects. For those investigators who have not been able to attend the previous web sessions, an additional session will be organized towards January.

Of course the study team in Seville and Antwerp are available for any questions by email and phone.

20/04/2024

EMA recommends Marketing Authorization for ATM-AVI

23/03/2024

Pfizer Receives Positive CHMP Opinion for its Novel Antibiotic Combination for the Treatment of Patients with Multidrug-Resistant Infections and Limited Treatment Options

COMBACTE is proud to announce a significant milestone achieved in COMBACTE-CARE. The European Medicines Agency (EMA) has recommended granting a market...

28/09/2023

REVISIT: A Novel Tool to Treat Highly-Resistant Pathogens?